05:05 PM EST, 11/05/2024 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) reported a Q3 net loss late Tuesday of $1.40 per diluted share, narrowing from a loss of $2.23 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.48.

Revenue in the three months ended Sept. 30 rose to $139.5 million from $98.1 million a year earlier. Analysts surveyed by Capital IQ expected $135.3 million.

The company expects 2024 revenue of $530 million to $550 million. Analysts polled by Capital IQ expect $537 million.

Shares of the company fell 5.8% in recent after-hours activity.

Price: 49.17, Change: -3.01, Percent Change: -5.77